Sheetal Shroff, MD
Neurology · Houston, TXNPI 1619270576
Payments from drug & device makers
Across 313 payments — averaging $1295.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$180K
- Alnylam Pharmaceuticals Inc.$52K
- UCB, Inc.$49K
- AstraZeneca$40K
- Argenx US, Inc.$33K
- Biohaven Pharmaceutical Holding Company Ltd.$27K
- plus $24K from 22 others
What the payments were for
- Consulting fees$33,09524%
- Speaking & faculty fees$90,58765%
- Travel & lodging$9,7287%
- Food & beverage$5,9904%
- Education$2790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 26 | $179,775 |
| Alnylam Pharmaceuticals Inc. | 59 | $51,933 |
| UCB, Inc. | 67 | $49,263 |
| AstraZeneca(2 entities) | 24 | $40,340 |
| Argenx US, Inc. | 54 | $33,177 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $26,861 |
| Tanabe Pharma America, Inc. | 11 | $19,376 |
| Novartis | 1 | $2,260 |
| Catalyst Pharmaceuticals, Inc. | 4 | $882 |
| Avanir Pharmaceuticals, Inc. | 24 | $407 |
| Biogen | 7 | $324 |
| Hospira, Inc. | 6 | $126 |
| Akcea Therapeutics, Inc. | 1 | $108 |
| Pfizer | 5 | $100 |
| Amgen | 3 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $78 |
| Johnson & Johnson | 1 | $45 |
| Merz North America, Inc. | 2 | $37 |
| EMD Serono, Inc. | 2 | $30 |
| Amylyx Pharmaceuticals, Inc. | 1 | $29 |
| Acorda Therapeutics, Inc | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| CSL Behring | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Sanofi | 1 | $19 |
| Strongbridge US Inc. | 1 | $17 |
| GRT US Holding, Inc. | 1 | $17 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$405,388 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 37 | $886,033 |
| Radicava OrsEdaravone | 41 | $614,468 |
| RystiggoRozanolixizumab-Noli | 12 | $583,316 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 63 | $465,519 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 45 | $398,588 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 14 | $175,108 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 26 | $160,058 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $145,891 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 17 | $101,881 |
| NuedextaDextromethorphan Hbr/Quinidine | 17 | $24,717 |
| Mycophenolate Mofetil | 51 | $9,570 |
| Pyridostigmine Bromide | 58 | $4,469 |
| Riluzole | 26 | $3,693 |
| Gabapentin | 92 | $3,179 |
| Almotriptan Malate | 11 | $2,562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Catalyst Pharmaceuticals, Inc.Firdapse | $882 | $886,03337 claims |
| UCB, Inc.Rystiggo | $49,263 | $583,31612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $78 | $465,51963 claims |
| CSL BehringHizentra, Privigen | $22 | $305,94939 claims |
| Amylyx Pharmaceuticals, Inc.Relyvrio | $29 | $175,10814 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $407 | $24,71717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.
Other neurology in Houston
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- John LindseyHouston$3.9M
- Joseph KassHouston$3.7M
- William OndoHouston$3.1M
- Vinay PuduvalliHouston$2.5M
- Erin Furr-StimmingHouston$2.1M
- Arjun TarakadHouston$2M
- Mazen DimachkieHouston$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.